Drug Profile
Research programme: small molecule therapeutics - Oscotec
Alternative Names: 4th Gen EGFR Inhibitor; 4th generation EGFR inhibitor; EGFR inhibitors - Genosco; Epidermal growth factor receptor inhibitors - Genosco; FGFR4 inhibitor; FLT3 inhibitor - Genosco; FMS-like tyrosine kinase-3 inhibitors - Genosco; LRRK2 inhibitors - GenoscoLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Oscotec
- Developer Genosco; Yuhan
- Class Antineoplastics; Antiparkinsonians; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists; LRRK2 protein inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Liver cancer; Non-small cell lung cancer; Parkinson's disease
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Non-small-cell-lung-cancer in USA
- 28 Apr 2023 No recent reports of development identified for research development in Liver-cancer in USA
- 05 Apr 2021 Early research is ongoing for liver cancer in USA (unspecified route) (Genosco pipeline, April 2021)